Nutriband Inc. (NTRB)
| Market Cap | 76.58M |
| Revenue (ttm) | 615,188 |
| Net Income (ttm) | -1.63M |
| Shares Out | 5.65M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | 250.00 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $12.50 |
| Previous Close | $12.50 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 12.50 |
| Day's Range | 12.50 - 12.50 |
| Day's Volume | 0 |
| 52-Week Range | 6.02 - 19.74 |
News
There are no news available yet.
About NTRB
Nutriband develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. Its product line consists of an energy patch line; a weight management patch line; a multivitamin patch line; a children's multivitamin patch line; an amino acid patch line; an anti-wrinkle patch line; an insect repellant patch line; a detox patch line; a PMS patc... [Read more...]
| Industry Biotechnology | |
| Stock Exchange OTCMKTS | Ticker Symbol NTRB |
Financial Performance
In 2019, Nutriband's revenue was $370,647, an increase of 51.11% compared to the previous year's $245,285. Losses were -$2.72 million, -18.30% less than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for Nutriband is 24.00, which is an increase of 92.00% from the latest price.